EAST WINDSOR, N.J. — Hovione, a fully integrated global contract development and manufacturing organization (CDMO), announced the completion of an initial $100 million investment cycle to expand its manufacturing site in East Windsor, New Jersey. When complete, the campus will span more than 200,000 square feet and feature state-of-the-art, sustainably designed facilities that strengthen Hovione’s integrated drug substance, drug product intermediate, and drug product capabilities in the United States.
The expansion includes a new 31,000-square-foot building that will house two size-3 spray dryers (PSD-3) for producing amorphous solid dispersions (ASDs), a key solubility enhancement technology used to improve drug bioavailability. The investment more than doubles Hovione’s U.S. spray drying capacity, supporting pharmaceutical companies seeking a reliable North American supply node for advanced manufacturing. Construction is underway, with GMP operations expected to begin in the second quarter of 2026.
“Since launching our New Jersey operations in 2002, Hovione has been one of the longest established European CDMOs in the United States,” said Jean-Luc Herbeaux, Ph.D., CEO of Hovione. “This investment reinforces Hovione’s leadership in spray drying – a core technology platform where we have built extensive know-how and capabilities. By continuing to advance our platforms and expand capacity in the U.S., we are strengthening the foundation that enables our partners to bring complex medicines to patients more efficiently.”
Dr. Herbeaux added, “This investment addresses growing customer demand for U.S.-based capacity and integrated solutions that shorten development timelines and reduce tech transfer complexity. By consolidating development, scale-up, and commercial manufacturing within a single quality and governance framework, we provide customers with seamless execution from drug substance to drug product.”
As part of the project, Hovione has also acquired adjacent land to support future expansion. The 125,000-square-foot greenfield space will accommodate large-scale production, including both continuous and batch tableting, and introduce new pharmaceutical technologies with advanced quality control and research capabilities.
“This expansion in New Jersey marks a significant step in extending our capabilities in the U.S., which go far beyond machine time or equipment capacity,” said David Basile, Vice President of Technical Operations – Americas at Hovione. “We are integrating our teams, specialized assets, proprietary technologies, and digital systems to deliver distinctive end-to-end ASD and continuous tableting platforms to our customers. Through our new strategic engagement model, customers can gain privileged access to innovation and assets that accelerate their programs and create long-term value.”
Hovione’s East Windsor expansion is part of a broader international growth strategy that also includes investments in Ireland and Portugal. Together, these sites will form a harmonized global network supporting development and commercialization of active pharmaceutical ingredients, intermediates, and finished drug products.
